AIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Fact Sheet Nr. 163.

[thumbnail of Fact Sheet Nr.163.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
135kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:English
Series Name:Fact Sheet Nr. 163
Deposited on:12 Feb 2024 17:37
Last Modified:12 Feb 2024 17:37

Repository Staff Only: item control page